We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 24, 2019

Edoxaban-Based vs Vitamin K Antagonist–Based Antithrombotic Regimen After Stenting in Atrial Fibrillation

The Lancet


Additional Info

The Lancet
Edoxaban-Based Versus Vitamin K Antagonist-Based Antithrombotic Regimen After Successful Coronary Stenting in Patients With Atrial Fibrillation (ENTRUST-AF PCI): A Randomised, Open-Label, Phase 3b Trial
Lancet 2019 Sep 02;[EPub Ahead of Print], P Vranckx, M Valgimigli, L Eckardt, J Tijssen, T Lewalter, G Gargiulo, V Batushkin, G Campo, Z Lysak, I Vakaliuk, K Milewski, P Laeis, PE Reimitz, R Smolnik, W Zierhut, A Goette

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading